--- title: "Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/296610788.md" description: "Tempus AI EVP Andrew Polovin sold 22,148 shares for ~$1.1M on Aug 18 via a Rule 10b5-1 plan to cover tax withholding, reducing his stake by 13.17%. CFO James Rogers also sold shares for tax purposes. Tempus AI recently beat Q2 earnings estimates with $382.49M revenue (+21.6% YoY) and a narrower loss of $0.04 per share. Analyst sentiment is mixed, with BTIG raising its target to $80 (Buy), while the consensus remains Hold at $65.69. Institutional investors like Victory Capital and Truist increased their holdings." datetime: "2026-08-21T11:22:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296610788.md) - [en](https://longbridge.com/en/news/296610788.md) - [zh-HK](https://longbridge.com/zh-HK/news/296610788.md) generator: "portal-rs" --- # Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock ## Key Points - **Tempus AI CFO James William Rogers sold 26,313 shares** at an average price of $60, generating $1.58 million. The Rule 10b5-1 sale was intended to cover tax withholding tied to vested equity awards, leaving him with 106,024 shares. - Tempus AI’s latest quarter exceeded expectations, reporting a loss of $0.04 per share versus the projected $0.14 loss and revenue of $382.49 million, up 21.6% year over year. - Analyst sentiment remains mixed: BTIG raised its price target to $80 and maintained a Buy rating, while the broader analyst consensus is Hold with an average target of $65.69. The stock recently opened at $66.65. Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) EVP Andrew Polovin sold 22,148 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the transaction, the executive vice president directly owned 146,067 shares in the company, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. - MarketBeat Week in Review – 02/23 - 02/27 Andrew Polovin also recently made the following trade(s): - On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total value of $443,912.00. ## Tempus AI Price Performance NASDAQ TEM opened at $66.65 on Friday. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The stock has a 50-day moving average of $52.44 and a 200 day moving average of $51.21. The company has a market capitalization of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. * * * * * * - After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. Tempus AI's revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current year. ## Institutional Trading of Tempus AI A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. Victory Capital Management Inc. lifted its position in shares of Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company's stock valued at $894,000 after buying an additional 162 shares in the last quarter. Truist Financial Corp grew its stake in shares of Tempus AI by 5.8% during the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company's stock valued at $209,000 after acquiring an additional 194 shares during the period. Farther Finance Advisors LLC increased its holdings in Tempus AI by 3.5% in the 4th quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company's stock worth $377,000 after acquiring an additional 219 shares in the last quarter. SeaCrest Wealth Management LLC increased its holdings in Tempus AI by 3.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company's stock worth $524,000 after acquiring an additional 229 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in Tempus AI by 29.4% during the 4th quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company's stock worth $65,000 after acquiring an additional 250 shares during the period. Hedge funds and other institutional investors own 24.22% of the company's stock. ## Wall Street Analysts Forecast Growth - Tempus AI Sold Off After a Beat—But the Rebound Case Is Building Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Tempus AI from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. Lake Street Capital cut shares of Tempus AI to a "hold" rating in a report on Monday, July 20th. Stifel Nicolaus decreased their price target on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a research report on Monday, August 3rd. Guggenheim increased their price target on shares of Tempus AI from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Finally, Wolfe Research began coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $65.69. **Read Our Latest Research Report on Tempus AI** ## Trending Headlines about Tempus AI Here are the key news stories impacting Tempus AI this week: - Positive Sentiment: **BTIG raised its price target to $80 from $70 and reaffirmed a “Buy” rating.** The new target implies approximately 20% upside from the referenced price and provides a direct catalyst for buying. BTIG raises Tempus AI price target - Positive Sentiment: Investors are increasingly focused on Tempus AI’s approximately **$1.5 billion all-stock acquisition of Personalis**. Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention - Positive Sentiment: Reported progress involving Moderna and Merck in cancer vaccines has improved sentiment toward genomic-data providers and made Tempus’ Personalis strategy appear more timely. The benefit to TEM is indirect, but the developments support the company’s oncology growth narrative. Tempus AI and cancer vaccine developments - Positive Sentiment: Call-option volume reached 40,671 contracts, about 57% above typical activity, signaling bullish speculation and potentially amplifying momentum. - Neutral Sentiment: TEM’s move above key moving averages has been described as a possible short squeeze. This can support further gains, but it also raises volatility and reversal risk. Tempus AI technical rally - Negative Sentiment: Several executives sold shares, including CEO Eric Lefkofsky, CFO James William Rogers and EVP Andrew Polovin. The sales totaled substantial amounts and reduced their holdings, which can concern investors. However, the transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling. ## Tempus AI Company Profile (Get Free Report) Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors. The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data. ## Featured Stories - Five stocks we like better than Tempus AI - Moderna’s 177% Surge Has Investors Asking What Comes Next - 3 Energy Stocks Raising Dividends as the Sector Surges - 5 Reasons the S&P 500 Could Keep Rallying Through Year-End - Walmart's Post-Earnings Drop Could Be a Buying Opportunity *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Tempus AI? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Tempus AI and related companies. From Our Partners ALERT: Drop these 5 stocks before the market opens tomorrow! The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc... Weiss Ratings Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top... InvestorPlace Ready to give options a try? Your first trade (Ticker included) -INSIDE Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st... Base Camp Trading Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c... Altimetry Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing My top 3 AI picks for the next decade Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A... The Oxford Club Buy this stock today Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo... Chaikin Analytics Here’s the stock symbol I’ve promised Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b... Stansberry Research ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md) - [VCTR.US](https://longbridge.com/en/quote/VCTR.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) ## Related News & Research - [Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock](https://longbridge.com/en/news/296562025.md) - [Tempus AI (TEM) Joins CellCarta Network, Is The Stock Still Undervalued?](https://longbridge.com/en/news/296430776.md) - [Tempus AI director Nadja West disposes of 3,000 common shares worth $161,700](https://longbridge.com/en/news/296265854.md) - [Tempus AI CFO James William Rogers disposes of USD 2.7 million in common shares](https://longbridge.com/en/news/296551053.md) - [Famous Hedge Fund Tiger Global Opened a New Position in This 1 AI Stock](https://longbridge.com/en/news/296381679.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**